samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > novel approaches to overcome crispr in vitro delivery challenges
PUBLICATIONS
European Biopharmaceutical Review

Novel Approaches to Overcome CRISPR In Vitro Delivery Challenges

The discovery and development of the CRISPR system as a gene editing tool has been a major revolution in life science, from human health in gene and cell therapy, agricultural sciences, to fundamental biology where it is now used as a standard tool (1). Although CRISPR is widely used in research laboratories, many challenges regarding delivery and safety remain to be overcome, for both in vivo and in vitro applications, to fulfil its potential.

Safety is a key concern when considering gene therapy. Offtarget mutations of the genome need to be minimised (2). This is also true when working in fundamental science, for example, when studying a signalling pathway where scientists need to ensure that the observed effect is caused by the targeted mutation and not off-target sites.

Another major challenge is the delivery of the CRISPR/Cas system into the nucleus of the targeted cells. In vivo is needed to pass through several barriers and be able to target a specific cell inside of a living organism. In vitro, the delivery of CRISPR/ Cas system components into cell nuclei is often limited by cytotoxic and low efficiency methods. Batch transfection using lipofectamine or electroporation is well suited when working with immortalised cell lines and performing single knock out, which requires the delivery of a single guide RNA (gRNA) together with the Cas9 protein. The inherent cytotoxicity of these standard methods is overcome by the high number of cells that are available. In turn, these methods are much less appropriate when working with hard-to-transfect cells, large repair templates for homologous directed repair, or for multiplexing projects where many edits are required. Here, the use of different and novel transfection approaches becomes critical.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Paul Monnier obtained his PhD in Molecular Biology from University Pierre and Marie Curie in Paris, France, while working on non-coding RNAs involved in epigenetic growth control of the embryo. After a postdoctoral position at ETH Zurich, Switzerland, and working on CRISPR genetic screens in stem cells and X-chromosome inactivation, he joined Cytosurge to set up their new biology lab. Here, he develops applications and protocols related to FluidFM technology in the life science field.
spacer
Dr Paul Monnier
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmaceutical companies go temporary to overcome pandemic challenges

Fast-tracking clinical trials, optimising energy intensive processes and improving yield are three ways in which temporary equipment is helping pharmaceutical companies amid the COVID-19 pandemic.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein´┐Żs primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement